Getinge AB (GNGBY) AI Stock Analysis

• Market Cap: $5.71B
• Dividend Yield: 0.13%
• Average Volume (3M): 382.00
• Price to Earnings (P/E): 39.3
• Beta (1Y): 0.54
• Revenue Growth: 9.03%
• EPS Growth: -40.47%
• Country: US
• Employees: 11,827
• Sector: Healthcare
• Sector Strength: 40
• Industry: Medical - Devices
• EPS (TTM): 0.20
• Shares Outstanding: 254,152,370
• 10 Day Avg. Volume: 0
• 30 Day Avg. Volume: 382
• PEG Ratio: -3.54
• Price to Book (P/B): 1.68
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 20.22
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $22.00
• Price Target Upside: 11.34% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

• Rating: 70 Outperform
• Price Target: $21.50 ▲(8.81%Upside)

Getinge AB's overall stock score is driven by its stable financial performance and positive earnings call outlook. While technical analysis and valuation present some concerns, the company's strategic focus on high-margin products and recurring revenue offers promising growth potential. Challenges from tariffs and currency fluctuations remain, but the company is well-positioned to manage these risks.

Getinge AB Business Overview & Revenue Model

Company Description

Getinge AB (publ) provides products and solutions for operating rooms, intensive-care units, and sterilization departments. The company operates through Acute Care Therapies, Life Science, and Surgical Workflows segments. It offers sterile transfer systems, closure processing systems, washers, isolators, sterilizers, logistic automation solutions, bioreactors, bioprocess control systems, bioprocess software, biobundles, bioprocess analytics, and perfusion systems; practice-oriented monitoring systems and disposables, anesthesia machines, beating heart stabilizers and positioners, axius blower mister and coronary shunts, proximal seal systems, ceiling supply units, connected solutions, cleaning and disinfection products, packaging and sealing solutions, monitors and indicators, and SteriTec products. The company also provides thoracic catheters, dry seal chest drain, mobile dry seal drain, dry and wet suction water seal chest drain, and chest drain valves; transitional accessories; endoscope reprocessing; endoscopic vessel harvesting systems; endovascular products; extracorporeal life support or extracorporeal membrane oxygenation products; inspection and packing products; intra-aortic balloon counter pulsation therapies; mechanical ventilation products; medical furniture; modular room systems; operating lights and tables; OR integration and management; patient flow management; patient transport; sterile supply management; sterilization; surgical assist systems; surgical perfusion; transport & storage; trays & baskets; and vascular and cardiothoracic surgery solutions. It offers its products through a network of proprietary sales companies, as well as through agents and distributors in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. Getinge AB (publ) was founded in 1904 and is headquartered in Gothenburg, Sweden.

How the Company Makes Money

Getinge AB generates revenue through the sale of its medical technology products and related services across various healthcare and life science sectors. The company's key revenue streams include the sales of equipment for operating rooms and intensive care units, such as ventilators, anesthesia systems, and surgical tables. Additionally, Getinge offers infection control solutions, including sterilization equipment and washer-disinfectors, which are integral to hospital operations. The company also provides service contracts, spare parts, and consumables associated with its products, which contribute to a recurring revenue model. Significant partnerships with healthcare institutions and research organizations globally further bolster its market presence and revenue generation.

Getinge AB Financial Statement Overview

Summary

Getinge AB demonstrates a stable financial position with strong profitability and a robust balance sheet. However, challenges in revenue growth and free cash flow decline slightly impact its overall financial health. Despite these challenges, the company maintains strong operational efficiency and low leverage, supporting its resilience in the medical devices industry.

Income Statement

Getinge AB has demonstrated solid performance in its income statement metrics. The gross profit margin for TTM (Trailing-Twelve-Months) stands at 46% and the net profit margin at 4.16%, indicating healthy profitability levels. However, the revenue growth rate for TTM is 2.32%, which shows moderate growth compared to previous periods. The EBIT margin is 7.79%, and the EBITDA margin is 17.28%, reflecting stable operational efficiency. Overall, the company maintains strong margins but exhibits limited revenue growth, which slightly dampens the score.

Balance Sheet

Getinge AB's balance sheet is robust with a debt-to-equity ratio of 0.38, indicating a conservative approach to leverage. The return on equity (ROE) for TTM is 4.84%, which is moderate, considering industry standards. The equity ratio is 50.68%, which demonstrates a strong equity base supporting its assets. The company maintains a solid financial structure with low leverage and a strong equity position, contributing to a high score in this vertical.

Cash Flow

The cash flow analysis for Getinge AB reveals mixed results. The free cash flow for TTM has decreased, leading to a negative growth rate of -24.02% compared to the previous year. However, the operating cash flow to net income ratio is 2.57, indicating strong cash generation relative to net income. The free cash flow to net income ratio is 1.68, showing efficient conversion of profit to cash. While operational cash generation remains strong, the decline in free cash flow growth impacts the overall score.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	34.76B	31.83B	28.29B	27.05B	29.82B
Gross Profit	16.15B	14.49B	13.41B	13.58B	14.72B
EBITDA	5.31B	5.91B	5.70B	6.15B	7.20B
Net Income	1.64B	2.41B	2.49B	2.97B	3.24B
Balance Sheet
Total Assets	63.92B	53.59B	52.03B	44.55B	45.01B
Cash, Cash Equivalents and Short-Term Investments	2.96B	2.73B	5.68B	4.08B	6.06B
Total Debt	10.73B	8.08B	5.82B	4.31B	10.21B
Total Liabilities	30.71B	23.18B	21.58B	19.38B	23.53B
Stockholders Equity	33.01B	30.17B	30.04B	24.75B	21.02B
Cash Flow
Free Cash Flow	3.27B	1.60B	2.23B	5.63B	6.15B
Operating Cash Flow	4.58B	2.96B	3.37B	6.56B	7.20B
Investing Cash Flow	-4.55B	-6.54B	-1.47B	-1.33B	-1.99B
Financing Cash Flow	504.00M	511.00M	-500.00M	-7.24B	-297.00M

Getinge AB Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 19.76
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GNGBY, the sentiment is Positive. The current price of 19.76 is below the 20-day moving average (MA) of 19.85, above the 50-day MA of 19.68, and above the 200-day MA of 18.77, indicating a neutral trend. The MACD of 0.05 indicates Positive momentum. The RSI at 50.44 is Neutral, neither overbought nor oversold. The STOCH value of 59.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GNGBY.

Getinge AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DXCM	78 Outperform	$32.89B	63.08	23.72%	―	9.11%	-17.87%
ZBH	74 Outperform	$18.44B	20.65	7.31%	1.04%	3.30%	-2.39%
EW	71 Outperform	$44.87B	51.15	16.73%	―	-9.84%	-35.77%
STE	71 Outperform	$22.19B	35.55	9.46%	1.02%	0.32%	64.36%
GNGBY	70 Outperform	$5.71B	39.27	4.80%	0.13%	9.03%	-40.47%
Sector *	54 Neutral	€4.62B	17.60	-48.29%	2.93%	15.32%	-9.52%
PHG	51 Neutral	$23.70B	―	-7.10%	3.61%	-0.76%	-55.03%